

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS


Joan M. Robbins and Richard Tritz

FILING DATE

October 25, 2000

GROUP ART UNIT

1614



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAL	AA	6,132,967	10/17/00	Grimm et al.	435	<del>6</del>	
KAL	AB	6,103,890	8/15/00	Jarvis et al.	<del>536</del>	<del>24.5</del>	
KAL	AC	5,929,040	7/27/99	Werther et al.	<del>514</del>	<del>44</del>	
KAL	AD	5,658,780	8/19/97	Stinchcomb et al.	<del>235</del>	<del>366</del>	
KAL	AE	5,646,042	7/8/97	Stinchcomb et al.	<del>435</del>	<del>366</del>	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	AF	✓	Frimerman et al., "Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model." <i>Circulation</i> 99:697-703, February 9, 1999
KAL	AG	✓	LaVail et al., "Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy." <i>Proceedings National Academy Science USA</i> 97(21): 11488-11493, October 10, 2000
KAL	AH	✓	Flores-Aguilar et al., "Evaluation of Retinal Toxicity and Efficacy of Anti-Cytomegalovirus and Anti-Herpes Simplex Virus Antiviral Phosphorothioate Oligonucleotides ISIS 2922 and ISIS 4015." <i>The Journal of Infectious Diseases</i> 175: 1308-1316, June 1997
KAL	AI		Taylor et al., "Chimeric DNA-RNA hammerhead ribozymes have enhanced <i>in vitro</i> catalytic efficiency and increased stability <i>in vivo</i> ." <i>Nucleic Acids Research</i> 20(17):4559-4565, 1992
KAL	AJ	✓	Morita et al., "Inhibition Of Rheumatoid Synovial Fibroblast Proliferation By Antisense Oligonucleotides Targeting Proliferating Cell Nuclear Antigen Messenger RNA." <i>Arthritis Rheumatism</i> 40(7):1292-1297, July 1997
KAL	AK		Gillardon et al., "Inhibition of c-Fos expression in the UV-irradiated epidermis by topical application of antisense oligodeoxynucleotides suppresses activation of proliferating cell nuclear antigen." <i>Carcinogenesis</i> 16(8): 1853-1856, 1995

EXAMINER

Karen Ojaconine

DATE CONSIDERED

10-16-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DCKET NO  
480124.407APPLICATION NO  
09/696,791

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary.)

APPLICANTS


Joan M. Robbins and Richard Tritz

FILING DATE

October 25, 2000

GROUP ART UNIT

1614



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	BA	✓	Jaskulski et al., "Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA Cyclin," <i>Science</i> 240: 1544-1546, June 10, 1988
KAL	BB		Capeans et al., "A c-myc Antisense Oligonucleotide Inhibits Human Retinal Pigment Epithelial Proliferation," <i>Exp. Eye Res.</i> 66: 581-589, 1998
KAL	BC		O'Neill et al., "Ribozyme-Based Therapeutic Approaches for Autosomal Dominant Retinitis Pigmentosa," <i>Investigative Ophthalmology &amp; Visual Science</i> 41(10): 2863-2869, September 2000
KAL	BD		Probst, J., "Antisense Oligodeoxynucleotide and Ribozyme Design," <i>Methods</i> 22: 271-281, 2000
KAL	BE		Kuang-Yu Jen and Alan M. Gewirtz, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> 18: 307-319, 2000

EXAMINER

Kane A. Lacombe

DATE CONSIDERED

10-16-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).